How CoCensys plans life after Novartis

Finding opportunity in adversity is critical to running a sustainable company. CoCensys Inc. (COCN, Irvine, Calif.) is trying to do just that after partner Novartis Pharma AG (Basel, Switzerland) said it would drop development of COCN's ACEA 1021 NMDA-receptor antagonist for stroke and head injury.

ACEA 1021 is a quinoxiline dione that competes with glycine for binding NMDA receptors, at a separate site from glutamate binding, to prevent the glutamate-induced calcium influx that results in nerve damage during stroke. The compound was originally licensed to Ciba-Geigy (now part of Novartis) in 1994 from Acea Pharmaceuticals Inc., at the same

Read the full 981 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE